Merck's (NYSE:MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg. Click here to find out ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...

Merck KGaA (Merck) is filing for global regulatory approvals of its CSF-1R inhibitor pimicotinib after it met the primary and ...

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

Merck and Daiichi Sankyo, which were seeking approval of patritumab deruxtecan for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Behind losses for shares of Merck and Nike, the Dow Jones Industrial Average is trading down Wednesday afternoon.